Browse the evidence

Sulfur amino acid restriction (SAAR) significantly decreases serum leptin levels and increases plasma ketone bodies (beta-hydroxybutyrate and acetoacetate) compared to a control diet, indicating a shift in metabolic fuel usage.

Reducing sulfur amino acids lowers leptin (a hormone that signals fat stores to the brain) and increases ketones. This suggests your body is switching to burning fat for fuel more efficiently, which may help sustain weight loss.

VLCD intervention significantly increases Sex-Hormone-Binding Globulin (SHBG) and reduces fasting blood glucose in obese women with PCOS, whereas moderate energy deficit does not significantly alter these specific metabolic markers over 8 weeks.

VLCDs offer a metabolic advantage over moderate dieting for PCOS patients by significantly boosting SHBG and lowering fasting glucose. This suggests VLCD may be necessary to reverse the underlying insulin resistance driving hyperandrogenism in some patients.

Metformin (1000 mg/day) produces a greater reduction in android fat mass (kg) compared to orlistat in obese premenopausal women, despite less total weight loss.

If your primary goal is reducing abdominal (android) fat rather than just total weight, metformin (1000mg/day) may be more effective than orlistat. This benefit comes with less overall weight loss, so the choice depends on your specific body composition goals.

Both orlistat and metformin produce comparable improvements in insulin sensitivity (ISI Matsuda) and post-load insulin levels in obese premenopausal women.

If your primary goal is improving insulin sensitivity, both orlistat and metformin are equally effective options over a 3-month period. The choice should be based on other factors like side effect tolerance or weight loss goals.

Fasting-based strategies improve insulin sensitivity (reduced fasting insulin and HOMA-IR) in the short term compared to continuous caloric restriction, but this benefit is not sustained in long-term outcomes for fasting glucose.

If you are obese, trying fasting strategies (like time-restricted eating) may help improve your insulin sensitivity in the first few months compared to just counting calories. This is measured by lower fasting insulin levels. However, this doesn't necessarily mean you will lose more weight in the long run, so use this metabolic benefit as one factor in choosing your strategy.

Intermittent fasting significantly improves lipid profiles by reducing total cholesterol and LDL, but may temporarily increase triglycerides in short-term interventions (≤ 12 weeks).

Intermittent fasting improves total cholesterol and LDL, key markers for heart health. However, be aware that triglycerides may temporarily rise in the first 12 weeks as your body adapts. This is often a transient phase. If you have high baseline triglycerides, consult a healthcare provider and consider longer-term adherence to see the full lipid benefits.

Intermittent fasting significantly reduces diastolic blood pressure but has no significant effect on systolic blood pressure, fasting plasma glucose, or HbA1c in overweight and obese adults.

Intermittent fasting can help lower diastolic blood pressure, a key component of heart health. However, it may not significantly affect systolic blood pressure or blood sugar levels (FPG, HbA1c) in the short term. For comprehensive cardiometabolic health, combine IF with other lifestyle interventions and monitor your specific markers.

A ketogenic diet significantly improves quality of life (QoL) and reduces fatigue symptoms in individuals with overweight, particularly those with high baseline fatigue.

If you are overweight and struggle with fatigue, a ketogenic diet may help boost your energy and overall quality of life. This benefit seems most pronounced if you already feel fatigued. Stick to the diet for at least three months, ensure you are in ketosis, and monitor how your energy levels change.

Reduction in chin subcutaneous adipose tissue (chin-SAT) is independently associated with improvements in glycemic control (fasting glucose, HbA1c, HOMA-IR) and lipid profiles, even after adjusting for changes in visceral adipose tissue (VAT) and waist circumference.

Losing chin fat may be a sign of improving metabolic health, specifically insulin sensitivity. While you cannot spot-reduce, the reduction of this specific fat depot correlates with better blood sugar control, independent of how much belly fat you lose.

Reduction in cervical subcutaneous adipose tissue (cervical-SAT) is independently associated with improvements in lipid profiles (triglycerides, LDL-C, cholesterol/HDL ratio) and leptin levels, independent of visceral adipose tissue (VAT).

Losing neck fat may be a sign of improving metabolic health, specifically lipid profiles and leptin sensitivity. While you cannot spot-reduce, the reduction of this specific fat depot correlates with better blood lipid control, independent of how much belly fat you lose.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) achieve 10-15% weight loss and superior metabolic improvements compared to lifestyle changes alone, but are recommended for non-responders or those with comorbidities.

If lifestyle changes alone do not achieve sufficient weight loss or if you have obesity-related comorbidities, discuss GLP-1 receptor agonists (like semaglutide or liraglutide) with your doctor. These medications can lead to 10-15% weight loss and significant metabolic improvements, though they may cause gastrointestinal side effects. They are most effective when combined with lifestyle modifications.

Tirzepatide produces significant weight loss (mean 18.73%) and improves quality of life in overweight or obese adults without diabetes, but significantly increases the risk of adverse events compared to placebo.

Tirzepatide is a highly effective treatment for weight loss in non-diabetic overweight or obese adults, producing an average 18.73% body weight loss. However, it comes with a significantly higher risk of adverse events, particularly gastrointestinal issues, compared to placebo. Patients should be monitored closely for these side effects.

Intermittent fasting downregulates enteroendocrine signaling, specifically GLP-1, GCG, and PYY, while upregulating PPAR-α, which correlates with improved lipid profiles.

The molecular changes observed (PPAR-α upregulation, GLP-1 downregulation) suggest that IF works by altering how your body processes fats and regulates hormones, not just by restricting calories. This may inform future targeted therapies.

Increasing the regularity of meal times (reducing mealtime variability) leads to significant weight loss without the need for calorie restriction or changes in macronutrient composition.

Use a smartphone app to track your meals for two weeks. Identify the specific times you eat most frequently. Then, for the next six weeks, restrict your eating to only those specific times, aiming for a consistency of within 45 minutes of your usual times. Do not worry about changing what or how much you eat. This regularity helps your body's internal clock optimize metabolism, leading to weight loss.

Semaglutide improves glycemic control and metabolic parameters in patients with Type 2 Diabetes and obesity.

For those with Type 2 Diabetes, semaglutide helps manage blood sugar and aids in weight loss, though the weight loss effect may be more modest compared to non-diabetic patients.

Central (intra-abdominal) fat is significantly more strongly linked to insulin resistance and cardiovascular disease than peripheral (gluteal/subcutaneous) fat.

Prioritize strategies that reduce visceral fat, such as aerobic exercise and stress management, as this type of fat is more metabolically active and harmful than subcutaneous fat.

A lower omega-6 to omega-3 fatty acid ratio (specifically 4:1 or lower) reduces total mortality and cardiovascular disease risk compared to the standard Western ratio of 15:1-16.7:1.

To improve heart health and reduce inflammation, shift your diet to lower the ratio of omega-6 to omega-3 fats. Aim for a ratio of 4:1 or lower. This means eating more fatty fish (salmon, mackerel) or taking fish oil supplements, while reducing intake of oils high in omega-6 like corn, soybean, and sunflower oils. Replace these with olive oil or canola oil, which have a more favorable profile. This shift helps reduce inflammation and cardiovascular risk.

Higher visceral adipose tissue (VAT) volume is more strongly associated with adverse metabolic risk factors (hypertension, dyslipidemia, diabetes, metabolic syndrome) than subcutaneous adipose tissue (SAT), and VAT provides significant risk prediction above and beyond standard anthropometric measures like BMI and waist circumference.

If you are concerned about metabolic health, standard weight and waist measurements may not tell the whole story. Visceral fat (fat around organs) is a more dangerous driver of risk than subcutaneous fat (fat under the skin). While you cannot easily measure visceral fat at home, maintaining a healthy weight and active lifestyle helps reduce it. If you have risk factors despite a 'normal' waist, deeper assessment of fat distribution might be relevant.

Obstructive sleep apnea (OSA) causes sustained high sympathetic nerve activity and blood pressure during sleep, which is significantly attenuated by continuous positive airway pressure (CPAP) treatment.

If you have obstructive sleep apnea, your body is under significant stress during sleep, with high blood pressure and nerve activity that don't drop as they should. Using CPAP therapy can significantly reduce this stress, lowering your blood pressure and sympathetic nerve activity to safer levels, which helps protect your heart and blood vessels.

Insulin resistance causes dyslipidemia characterized by high triglycerides, low HDL, and small dense LDL, which significantly increases the incidence of cardiovascular disease.

Insulin resistance changes your lipid profile in a dangerous way: high triglycerides, low HDL, and small dense LDL. This specific combination is highly atherogenic. Managing insulin sensitivity is key to improving this profile.

Dietary fiber fermentation by gut microbiota produces short-chain fatty acids (SCFAs) which stimulate the secretion of gut peptides (GLP-1, PYY) via GPR41/GPR43 receptors, thereby improving glucose regulation and reducing energy intake.

To leverage your gut microbiome for better blood sugar control and appetite regulation, consume complex carbohydrates (dietary fibers) that resist digestion in the small intestine. These fibers reach the colon where bacteria ferment them into short-chain fatty acids (SCFAs). These SCFAs activate specific receptors (GPR41/43) on gut cells, triggering the release of hormones like GLP-1 and PYY that improve glucose handling and reduce hunger. Focus on sources like resistant starches and arabinoxylans.

Anti-inflammatory therapies targeting specific pathways (e.g., IKKbeta/NF-kB inhibition with salicylate, IL-1 blockade with anakinra) can improve glycemic control and insulin sensitivity in patients with type 2 diabetes.

While not a lifestyle intervention, research shows that reducing specific inflammatory pathways (like IKKbeta/NF-kB) can improve blood sugar control in diabetes. This highlights the importance of inflammation in metabolic disease.

Dietary intake of fermentable carbohydrates (fiber, resistant starch, prebiotics) increases the production of short-chain fatty acids (SCFAs) like butyrate and propionate in the colon, which contributes to gut barrier integrity, reduced inflammation, and metabolic health benefits.

To support your gut health and metabolism, prioritize foods rich in fermentable fibers like vegetables, fruits, whole grains, and legumes. These feed your gut bacteria to produce beneficial short-chain fatty acids (SCFAs) that support your gut barrier and metabolic health. If you are currently low in fiber, increase your intake gradually to minimize digestive discomfort.

Long sleep duration (≥9 hours per night) is associated with a significantly increased risk of coronary heart disease (RR 1.38), stroke (RR 1.65), and total cardiovascular disease (RR 1.41) compared to the reference group of 7-8 hours.

Aim for 7-8 hours of sleep per night. Consistently sleeping 9 hours or more per night is associated with a higher risk of heart disease and stroke. If you consistently need 9+ hours of sleep, it may be a marker of underlying health issues (such as depression or undiagnosed conditions) and should be discussed with a healthcare provider.